Weekly semaglutide improves blood sugar and weight in adults with Type 1 diabetes
A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with Type 1 diabetes who use automated insulin delivery systems.
The results were published today in the journal NEJM Evidence.
Semaglutide is a medication that belongs to a class of drugs known as glucagon-like peptide-1, or GLP-1, receptor agonists. Sold under the trade names such as Ozempic, Wegovy and Rybelsus, the drug was initially developed for the treatment of Type 2 diabetes, helping to manage blood sugar levels.
The 26-week, double-blind study involved ...